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ABSTRACT
Objective: Malaria infection remains a global concern due to increasing resistance to artemisinin-based combination therapy. This study examined 
the antimalarial effects of propolis extract alone and in combination with pasak bumi root extract.
Methods: In the study, 30 mice were divided into six groups including two control groups, two groups of mice treated with propolis alone 
at concentrations of 90 and 180 mg/kg body weight (BW), and two combination groups of mice treated with 90 or 180 mg/kg BW propolis in 
combination with 60 or 75 mg/kg BW pasak bumi, respectively. Plasmodium berghei 2% was injected into each mouse, and blood smears were 
prepared after 8 days to assess parasitemia.
Results: The results revealed no significant difference in parasitemia levels between the positive control and the two combination groups (p=0.136 and 
0.289, respectively). However, superior growth inhibition (GI) results were observed in the combination groups (97.97% and 97.83%, respectively) 
than in the propolis monotherapy groups, whereas better outcomes were observed in the positive control group (98.63% GI) than in the propolis 
monotherapy groups (23.88% and 51.66%, respectively).
Conclusion: These results illustrate that combination therapy is superior to propolis monotherapy in inhibiting parasitemia.
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INTRODUCTION
Malaria is an infectious disease caused by Plasmodium parasites and 
transmitted by Anopheles mosquitoes [1]. According to the World 
Health Organization (WHO) data, malaria was linked to 438,000 deaths 
globally in 2015 [2]. In Indonesia, the incidence of malaria has reached 
2.9%, up from 1.9% in 2013. The incidence and prevalence of malaria 
are highest in Papua, East Nusa Tenggara, West Papua, Central Sulawesi, 
and Maluku [3].
Malaria remains prevalent due to resistance to malaria therapy [2]. In 
Indonesia, chloroquine is used for antimalarial therapy, but resistance 
to artemisinin-based combination therapy (ACT) first appeared in 
2004 [4,5]. Similarly, the resistance of Plasmodium falciparum to ACT 
has also been detected in Cambodia, Laos, Myanmar, Vietnam, and 
Thailand [2]. However, the WHO continues to recommend ACT due to 
its efficacy [6].
At present, other alternatives for treating malaria have been 
investigated, such as the use of pasak bumi (Eurycoma longifolia) and 
propolis. Pasak bumi root has displayed antimalarial effects in both 
in vivo and in vitro studies [7]. In addition, the antimalarial effects 
of pasak bumi are stronger than those of chloroquine [8]. Research 
on the usefulness of propolis and its components has been widely 
conducted. Chalcone compounds in propolis reduce hemolysis induced 
by isosorbide by ≤40%, demonstrating its good anti-Plasmodium 
effects [9]. Recently, propolis has increasingly been studied for its 
antimalarial effects [10]. As antimalarial therapy, pegs can be combined 
with ACT and chloroquine. Pre-existing research has examined the 
combination of chloroquine and propolis as antimalarial therapy, but 
no research has assessed the combination of pasak bumi and propolis. 
Therefore, this study analyzed the combination of pasak bumi and 
propolis in the treatment of malaria [7,11].
METHODS
This in vivo study was conducted at the Try Animal Laboratory of the 
Ministry of Health of Indonesia, Parasitology Laboratory of FKUI, and 
RIK Laboratory of Depok between April 2016 and December 2016. 
The study subjects were healthy (active) Mus musculus (Swiss) mice 
(3–4 months old, 20–30 g). Mice with defects or those that died during 
experimentation were excluded from the analysis. The independent 
variables were the concentration and type of treatment given to the 
experimental groups. The dependent variable was the parasitemia level 
in mice.
In the study, mice were divided equally into six groups in cages marked 
with picric acid as follows:
1. Group 1: Negative control (K−) infected with 0.2 ml of Plasmodium 
berghei 1% without any therapy.
2. Group 2: Positive control (K+) infected with 0.2 ml of P. berghei 1% 
and treated with ACT 1.7 mg/kg body weight (BW) orally for the first 
3 days after infection.
3. Group 3: Treatment 1 (K1) infected with 0.2 ml of P. berghei 1% and 
treated with oral propolis 75 mg/kg BW for 4 days.
4. Group 4: Treatment 2 (K2) infected with 0.2 ml of P. berghei 1% and 
treated with oral propolis 150 mg/kg BW for 4 days.
5. Group 5: Treatment 3 (K3) infected with 0.2 ml of P. berghei 1% and 
treated with a combination of pasak bumi 60 mg/kg BW and propolis 
90 mg/kg BW daily for 4 days.
6. Group 6: Treatment 4 (K4) infected with 0.2 ml of P. berghei 1% and 
treated with a combination of pasak bumi 75 mg/kg BW and propolis 
180 mg/kg BW daily for 4 days.
P. berghei was grown and propagated in donor mice. P. berghei 
obtained from the Department of Parasitology at FKUI was injected 
intraperitoneally into donor mice at a volume of as much as 1 ml. The 
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mice were then incubated until a parasitemia level of 2% was achieved 
as determined through blood sampling. Blood was then diluted using 
Roswell Park Memorial Institute at a ratio of 1:9. In total, 0.2 ml of 
diluted blood was injected intraperitoneally into mice. Treated mice 
were incubated for 24 h, after which blood was obtained daily through 
the tail vein without anesthesia to assess parasitemia through Giemsa 
staining using standard procedures [12].
Parasitemia in 1000 erythrocytes was examined using a microscope 
with ×1000 magnification and oil emersion. The percent parasitemia 
was determined using the following formula:
% Parasitemia = (Number of infected erythrocytes/Total number of 
erythrocytes)×100
The percent growth inhibition (GI) was calculated using Peter’s 4-day 
suppressive test method through the following formula:
GI = ([Parasitemia K(−)−Experimental group])/(Parasitemia K[−])×100
Note: K (−) = Negative control.
The dihydroartemisinin-piperaquine (DHP) dose was determined as 
follows:
Human dose=Mouse dose×mouse factor/human factor.
4 mg=Mouse dose×3/37.
Mouse dose=49.3 mg/kg BW.
The DHP dose obtained using the formula was 49.3 mg/kg BW. This 
dose was diluted to 1 mg/ml.
One propolis tablet contains 500 mg of propolis. The crushed tablet 
was then diluted with distilled water to doses of 90 and 180 mg/kg BW 
versus the use of doses of 25, 50, and 100 mg/kg BW per day in a prior 
study [13].
Pasak bumi extract was generated by diluting pasak bumi powder with 
Aqua Dest. The available extract concentration is 2 g/50 ml water (65% 
active ingredient). The concentration of the extract was adjusted to the 




N1=Parasitemia concentration of donor mice.
V2=Volume of pasak bumi extract.
N2=Concentration of parasitemia desired.
RESULTS
Figure 1 presents microscopic images of erythrocytes from control and 
infected mice. On the 4th day, the positive control erythrocytes remain 
intact and healthy (Fig. 1a). Conversely, the infected parasites appeared 
pale (Fig. 1b).
As shown in Table 1, the parasitemia level increased each day in the 
negative control group. Conversely, parasitemia levels remained low in 
the positive control group, with the lowest level observed on day 3.
Meanwhile, parasitemia levels were lower in the propolis monotherapy 
groups than in the negative control group, whereas the levels were 
dramatically elevated versus those in the positive control group. 
However, a dose-dependent effect of propolis was observed.
In both combination treatment groups, parasitemia levels increased 
until day 1 before declining on subsequent days, with stronger 
antimalarial effects observed with the higher doses of pasak bumi and 
propolis. On day 4, the levels of parasitemia in both combination groups 
were similar to those of the positive control.
GI
The results for inhibition of parasitemia are summarized in Figs. 2 and 3.
The results illustrated that the greatest GI was observed in the K+ 
group followed by the K3 and K4 groups. Meanwhile, weaker effects 
were observed in the K1 and K2 groups, particularly the K1 group. 
Table 2 outlines the relationship between the level of parasitemia and 
GI from day 0 to day 4. The data illustrated that the parasitemia level 
was inversely proportional to GI.
Statistical analysis of parasitemia
Differences in parasitemia between days 0 and 4 were examined 
through a suppressive test method. These data were tested for 
normality using the Shapiro–Wilk test, whereas the Kruskal-Wallis test 
was used to identify significant differences. The results of the analysis 
are presented in Table 3.
Post hoc analysis of these differences was performed using the Mann–
Whitney U-test as presented in Table 4.
The results illustrated significant differences between the K1 group 
and the K3 and K4 groups. Similarly, significant differences were noted 
between the K2 group and the K3 and K4 groups. However, the results 
Fig. 3: Growth inhibition by the combination treatment
Fig. 2: Growth inhibition by propolis monotherapy
Fig. 1: Microscopic images of erythrocytes. (a) Positive control, 
the cells appear healthy and intact. (b) Negative control, the cells 
display visible signs of infection
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in both combination groups were not significantly different from those 
of the positive control.
DISCUSSION
This study compared propolis monotherapy at two doses to combination 
treatment with propolis and pasak bumi. The doses of pasak bumi 
were based on Ridzuan’s research using P. yoelli and a separate study 
by Adiprameswari [7,14]. The studies illustrated that pasak bumi 
enhanced the effects of both artemisinin and chloroquine when used in 
combination. Similarly, the combination of pasak bumi and propolis is 
also expected to provide stronger effects against parasitemia.
The effects of propolis monotherapy and combinations on parasite 
growth
The study results indicated that propolis alone had weaker effects on 
parasite growth than the positive control ACT, although the higher dose 
of propolis more strongly suppressed parasitemia than the lower dose. 
This finding is in line with research conducted by Syamsudin stating 
that propolis has dose-dependent effects on parasitemia. Similarly, 
studies conducted by Syamsudin and Olayemi also revealed that 
propolis monotherapy resulted in higher levels of parasitemia than 
treatment with chloroquine [13,15]. However, the dose of propolis 
should not exceed the toxic dose of 7.34 g/kg BW in mice or 50 g/ml 
in patients, as the therapy is ineffective above this threshold [16,17].
Propolis, when combined with pasak bumi, had longer-lasting effects 
against parasitemia than the positive control, leading to suppressed 
parasite growth on day 3. A study by Olayemi similarly identified a peak 
difference in activity between chloroquine and propolis, resulting in 
different effects [15]. The differences could also be due to the use of 
impure extracts. In this study, a crude propolis extract that was obtained 
commercially was used, and thus, the results are likely different for 
propolis obtained through pure extraction or diffraction [17].
The results of the study indicated that propolis and pasak bumi 
had synergistic effects against parasitemia. Prior research similarly 
demonstrated that pasak bumi was more effective when used in 
combination with other treatments than as monotherapy [7]. Similar 
outcomes have also been reported for propolis [15,17].
Table 1: Parasitemia levels
Group n Parasitemia level (%) Day 4–Day 0
Day 0 Day 1 Day 2 Day 3 Day 4
Negative control 5 0.52 7.46 20.24 42.78 45.22 44.70
Positive control 5 0.52 1.72 0.96 0.48 0.62 0.10
Propolis 90 mg/kg BW 5 0.74 3.76 11.96 26.44 34.42 33.68
Propolis 180 mg/kg BW 5 0.64 1.34 7.6 18.04 21.86 21.22
Propolis 90 mg/kg BW+PB 60 mg/kg BW 5 0.58 5.5 4.62 1.96 0.92 0.34
Propolis 180 mg/kg BW+PB 75 mg/kg BW 5 1.08 3.46 2.54 1.52 0.98 −0.1
Parasitemia was assessed starting 24 h after Plasmodium infection, N: Number of mice per group, PB: Pasak bumi, Negative control = Mice infected without treatment, 
Positive control = Mice infected and treated with artemisinin combination therapy
Table 2: Relationship between parasitemia and growth inhibition
Group n Parasitemia levels and GI (%)
Day 0 Day 1 Day 2 Day 3 Day 4
P GI P GI P GI P GI P GI
Negative control 5 0.52 0 7.46 0 20.24 0 42.78 0 45.22 0
Positive control 5 0.52 0.00 1.72 76.94 0.96 95.26 0.48 98.88 0.62 98.63
Propolis 90 mg/kg BW 5 0.74 −42.31 3.76 49.60 11.96 40.91 26.44 38.20 34.42 23.88
Propolis 180 mg/kg BW 5 0.64 −23.08 1.34 82.04 7.6 62.45 18.04 57.83 21.86 51.66
Propolis 90 mg/kg BW+PB 60 mg/kg BW 5 0.58 −11.54 5.5 26.27 4.62 77.17 1.96 95.42 0.92 97.97
Propolis 180 mg/kg BW+PB 75 mg/kg BW 5 1.08 −107.69 3.46 53.62 2.54 87.45 1.52 96.45 0.98 97.83
Parasitemia and growth inhibition were assessed starting 24 h after Plasmodium infection, n: Number of mice per group, P: Parasitemia level, GI: Growth inhibition, 
Negative control = Mice infected without treatment, Positive control = Mice infected and treated artemisinin combination therapy, PB = Pasak bumi
Table 3: Differences of parasitemia levels between days 0 and 4
Group n Brinkman index p value
Positive control 5 0.00 (−0.10–0.40) <0.05
Negative control 5 50.70 (8.30–65.40)
Propolis 90 mg/kg BW 5 32.50 (1.30–65.00)
Propolis 180 mg/kg BW 5 26.00 (22.70–27.60)
Propolis 90 mg/kg BW+PB 
60 mg/kg BW
5 0.30 (0.00–0.70)
Propolis 180 mg/kg BW+PB 
75 mg/kg BW
5 −0.10 (−0.70–0.80)
Kruskal–Wallis test, PB: Pasak bumi, BW: Body weight
Table 4: Post hoc analysis of differences in parasitemia levels 
between days 0 and 4




Propolis 90 mg/kg BW 0.009
Propolis 180 mg/kg BW 0.009
Propolis 90 mg/kg BW+PB 60 mg/kg BW 0.136
Propolis 180 mg/kg BW+PB 75 mg/kg BW 0.289
Negative control
Propolis mg/kg BW 0.251
Propolis mg/kg BW 0.117
Propolis mg/kg BW+PB 60 mg/kg BW 0.009
Propolis 180 mg/kg BW+PB 75 mg/kg BW 0.009
Propolis 90 mg/kg BW
Propolis 180 mg/kg BW 0.465
Propolis 90 mg/kg BW+PB 60 mg/kg BW 0.009
Propolis 180 mg/kg BW+PB 75 mg/kg BW 0.009
Propolis 180 mg/kg BW
Propolis 90 mg/kg BW+PB 60 mg/kg BW 0.009
Propolis 180 mg/kg BW+PB 75 mg/kg BW 0.009
Propolis 90 mg/kg BW+PB 60 mg/kg BW
Propolis 180 mg/kg BW+PB 75 mg/kg BW 0.141
Post hoc Mann–Whitney U-test, PB: Pasak bumi, BW: Body weight
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CONCLUSION
The combination of pasak bumi root extract and propolis had better 
effects against parasitemia than propolis monotherapy in mice infected 
with P. berghei.
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